Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessSangamo Shares Plummet 56 percent as Pfizer Ends Hemophilia A Gene Therapy...

Sangamo Shares Plummet 56 percent as Pfizer Ends Hemophilia A Gene Therapy Partnership

Add to Favorite
Added to Favorite


Sangamo Therapeutics (NASDAQ:SGMO) faced a significant setback as Pfizer announced the termination of their partnership to co-develop a gene therapy for hemophilia A, causing Sangamo’s stock to plummet 56% on Tuesday. The decision leaves Sangamo regaining full rights to the program but significantly delays its path to regulatory approval.
The collaboration’s dissolution comes after Pfizer conducted a thorough evaluation of clinical trial data, expert opinions, and market trends. The pharmaceutical giant cited limited patient interest and slow adoption of gene therapies for moderate to severe hemophilia A as key reasons for stepping away from the project. Pfizer emphasized its intent to focus resources on treatments with a higher likelihood of commercial success.
Previously, late-stage trial results showed the therapy’s potential to reduce bleeding episodes in hemophilia A patients. However, Pfizer’s withdrawal halts plans to submit regulatory approval data, initially expected in early 2025, leaving Sangamo to determine the program’s next steps. The company is exploring new collaboration opportunities or alternative pathways to continue development. The agreement will formally end on April 21, 2025, allowing trial participants to remain under observation during the transition.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Jaguar Mining Inc. Financial Performance and Outlook

Earnings per share of $0.09 fell short of the...

Gold Prices Surge: UBS Forecasts Up to $3,500/oz Amid Global Uncertainty

Introduction Gold prices have surged in March, surpassing $3,100 per...

Goldman Sachs Cuts STOXX 600 Outlook Amid Trade and Growth Concerns

Goldman Sachs has lowered its 12-month forecast for Europe’s...

Bitcoin Rebounds After Q1 Selloff; Trump’s Crypto Moves in Focus

Bitcoin Recovers Amid Broader Market Rebound Bitcoin (BTC) edged 1.3%...